July 6th, 2016
National Institute of Allergy and Infectious Diseases (NIAID) has awarded Agilvax a one-year, $286,000 grant under the Small Business Innovation Research (SBIR) program entitled “Development of a VLP-based RSV vaccine targeting pre-fusion F protein.”
Respiratory Syncytial Virus (RSV) is responsible for over 30 million new acute lower respiratory infections in children under five, which results in more than 3.4 million hospital admissions, according to the World Health Organization. RSV also impacts adult populations resulting in 177,000 hospitalizations and 14,000 deaths in adults older than 65 years in the United States alone, according to the Centers of Disease Control and Prevention. Thus, the development of an RSV vaccine is paramount to treat the world’s most vulnerable populations; children and the elderly.
“We are excited to be recognized with this highly competitive award from the NIH,” said Federica Pericle, President and CEO. “This award provides a vital springboard to further the development of our novel RSV vaccine. It also validates our unique VLP platform technology for the development of vaccines against diseases with high unmet clinical need.”
Agilvax (www.agilvax.com) is a biotechnology company that is developing targeted vaccines and cancer stem cell immunotherapies based on a proprietary virus-like particle (VLP) platform technology. The technology integrates epitope identification and immunogenic presentation in a single platform. The Company was founded in 2011 and has headquarters in Albuquerque, NM and offices in El Paso, TX.